Hepatitis B Vaccine Policy Shift Raises Alarm Over Infant Health Risks
A major shift in hepatitis B vaccination policy in the United States is now triggering serious concern among infectious disease experts, as new studies warn it could lead to preventable infant infections, long-term illness and even deaths.
At the center of the debate is a change in guidance that moves away from a long-standing recommendation: giving all newborns a hepatitis B vaccine at birth. Instead, the updated approach suggests the birth dose should mainly be given to babies considered at risk, such as those born to mothers who tested positive for the virus or were not screened during pregnancy. For infants born to mothers who tested negative, the first vaccine dose may be delayed until around two months of age.
Researchers now say that change could have measurable consequences. Two new modeling studies published in JAMA Pediatrics project that delaying or narrowing access to the birth dose could lead to increased infections in newborns each year. One analysis estimates dozens of additional chronic infections annually, along with tens of deaths and millions of dollars in added healthcare costs. Another model suggests the impact could be even larger if vaccination coverage drops significantly among infants who are supposed to receive early protection.
Also Read:- Stockport Quiz Whiz Wins £1M on Millionaire After Stunning Final Answer
- Mariners Look to Extend Road Streak as Twins Fight to Stop Slide
What makes this particularly concerning is how hepatitis B behaves in newborns. While many healthy adults can clear the virus, infants infected at birth face a very high risk of developing chronic infection, around 90 percent. That chronic condition can silently progress over years and eventually lead to severe liver disease or early death.
Experts also warn that the real-world impact may go beyond the numbers in the models. When vaccination stops being routine and becomes conditional, coverage often falls. Hospitals and clinicians may face added complexity and some newborns, especially those born to mothers who missed screening or prenatal care, could fall through the gaps entirely.
Public health researchers say the previous universal birth dose strategy played a key role in dramatically reducing infant hepatitis B cases over decades. They argue that weakening that system could reverse some of those gains, even if unintentionally.
As states, health agencies and medical groups respond differently to the new guidance, uncertainty is growing over how widely it will be adopted in practice. Some jurisdictions have already signaled resistance, adding further fragmentation to an already complex public health landscape.
This remains a developing policy shift with significant implications for infant health, vaccination programs and long-term disease prevention strategies. Stay tuned here for continuing coverage as this story evolves and global health experts assess the real-world impact in the months ahead.
Read More:
0 Comments